Alternative splicing (AS) is assumed to be a pivotal determinant for the generation of diverse transcriptional variants in cancer. However, the comprehensive dysregulation of AS and the prospective biological and clinical relevance in hepatocellular carcinoma (HCC) remain obscure. Here, we identified and depicted the AS landscape in HCC by performing reference-based assembly of sequencing reads from over 600 RNA sequencing (RNA-seq) libraries. We detected various differentially spliced ASEs across patients covering not only protein-coding genes, but also considerable numbers of noncoding genes. Strikingly, alternative transcription initiation was found to frequently occur in HCC. These differential ASEs were highly related to "cancer hallmarks" and involved in metabolism-related pathways in particular. In addition, 243 differential ASEs were identified as risk predictors for HCC patient survival. The isoform switch of metabolism-related gene UGP2 (UDP-glucose pyrophosphorylase 2) might play an essential role in HCC. We further constructed regulatory networks between RNA-binding protein ( H epatocellular carcinoma (HCC) is the most common type of primary liver cancer, which is currently the second-leading cause of death from cancer worldwide.
H epatocellular carcinoma (HCC) is the most common type of primary liver cancer, which is currently the second-leading cause of death from cancer worldwide. (1) Malignance is induced by many pathogenic factors, primarily including infection with hepatitis B virus (HBV) and hepatitis C virus (HCV), alcohol use, and aflatoxin B1 exposure. (1) (2) (3) The dismal prognosis and limited effective treatments for HCC patients is currently motivating the development of early diagnostic and prognostic biomarkers, even reliable therapeutic targets.
In-depth research on other types of cancer and pilot studies in HCC suggest that a comprehensive investigation of the alterations of the HCC transcriptome is critically important to gaining a better understanding of the biological processes of HCC and will provide opportunities for the discovery of novel molecular biomarkers and therapeutic targets. (4) (5) (6) (7) The rise and rapid developing of high-throughput RNA sequencing (RNA-seq) technology and the applications thereof provide a powerful approach for transcriptome research.
A growing number of genome-wide studies have revealed that the human genome has far fewer genes, or genomic space, for the rich transcriptome and entire proteome. (9) (10) (11) Approximately 95% of multiexon human genes produce various transcripts through alternative splicing (AS), which shapes the diverse delivery of genetic information. The AS process plays important roles in tissue identity and numerous critical biological processes. Disruption of AS has been proven to cause various diseases, including cancer. (12) (13) (14) In recent years, the perturbation of AS has been described in various types of cancer. (14, 15) Transcriptomic analyses in HCC have revealed not only expression dysregulation of many genes, (16, 17) but also splicing aberrations of certain genes. (7, 17) For example, Numb expressed a higher level of an isoform containing a long proline-rich region (PRR) compared with that of another isoform with a short PRR in HCC. (7) The isoform with a long PRR is significantly associated with early recurrence and a decrease in overall survival after surgery, which might make the isoform a useful prognostic biomarker for HCC. However, comprehensive alterations of AS and their biological/clinical implications in a large HCC cohort remain uncharacterized.
Various regulatory properties contribute to the perturbation of AS in cancer, wherein cis-acting regulatory sequences and trans-acting RNA-binding proteins (RBPs) play a prominent role. (18) (19) (20) Multiple studies have shown that RBP proteins can promote exon inclusion or skipping by binding to splicing regulatory elements; thus, alterations in levels and activity of RBPs would lead to AS dysregulation. (21) (22) (23) Increasing evidence indicates that deleterious mutations (including nonsense, missense, and even translationally silent mutations) residing within splicing regulatory regions exert effects on pre-mRNA splicing in human diseases. (24) For example, a recent pan-cancer study revealed how point mutations can alter repertoires of splicing isoforms by connecting thousands of mutation-splicing relationships across 33 types of cancer. (25) Nevertheless, understanding of the dysregulation of splicing machinery components in HCC remains unclear.
To unravel the dysregulation enigma of the HCC transcriptome, we gathered a large collection of HCC-related data/samples to comprehensively interrogate the human transcriptome in the liver through a reference-based assembly of sequencing reads. We depicted the expansive landscape of transcription and its diversity (mainly induced by AS) in the human liver. Further analysis revealed prevalent alterations of AS and their biological/clinical implications in HCC. Moreover, we investigated the dysregulation of AS by RBP, constructing RBP dysregulation networks in HCC. By uncovering the transcription diversity and dysregulation of AS in HCC, we provide the scientific community with a valuable resource for the exploration of AS dysregulation and the study of diagnostic/ prognostic biomarkers in HCC.
Materials and Methods

HUMaN SUBJeCtS aND DataSetS
We collected 46 tissue samples and 8 cell lines for high-throughput sequencing of RNA (Supporting Table S1 ). Tissue samples included 17 samples from primary HCC tumor tissue, 22 from adjacent normal liver tissue, 5 from relapse HCC tumor and 2 from aRtiCle iNFoRMatioN: normal liver tissue. All human materials were obtained with informed consent and approved by the ethical committee. In addition, 100 primary HCC tumor samples and 50 adjacent normal liver tissue samples obtained from GEO (GSE77314 and GSE65485) were included in this study. For normal liver tissue, we obtained another 6 samples from ENCODE. In total, 117 primary tumor, 5 relapse HCC tumor, 8 HCC cell line, 72 adjacent normal liver and 8 normal liver tissue samples were curated, and all corresponding RNA-seq data were generated using the Illumina sequencing platform. Additionally, the aligned RNAseq reads (bam files) of a TCGA LIHC cohort including 371 tumor and 50 adjacent non-tumor samples were downloaded from the GDC data portal (https:// portal.gdc.cancer.gov/) with official authorization.
tRaNSCRiptoMe aSSeMBly aND QUaNtiFiCatioN FRoM RNa-SeQ Data
The quality of raw RNA-seq data was first evaluated by using FastQC v0.11.3 (https://www.bioinformatics.bbsrc.ac.uk/projects/fastqc). FastQC results showed that all raw reads were qualified for downstream analysis. Afterward, all reads were aligned to the human reference genome (hg38) using STAR software (version 2.4.2a). (26) Specifically, a two-step mapping strategy was used to utilize splice junctions from each sample, which was consistent with the GDC (Genomic Data Commons) STAR alignment pipeline for liver hepatocellular carcinoma (LIHC) cohort samples. In the first round of read mapping, STAR was provided with the index downloaded from the GDC. At the end of the first mapping step, a new index was generated by combining splice junctions. Then, a second round of mapping was performed with the new index generated in the first step. The read alignments obtained from the above-mentioned two-step mapping was provided as input to StringTie (version 1.2.3) (27) for transcriptome assembly. Annotation from GENCODE version 22 (28) was used as the transcript model reference to guide the assembly process with the "-G" option. GENCODE version 22 annotated 60,483 genes, including 19,814 protein-coding genes, 15,900 long noncoding genes, and 14,285 pseudogenes. Specifically, transcripts were assembled individually for each sample. Then, StringTie was run in "--merge" mode to generate a nonredundant master set of transcripts observed in all the RNA-seq samples assembled above. The Cufflinks program (29) was used to produce expression levels for the merged transcriptome in each sample at the gene and transcript levels in FPKM units (FPKM = Fragments Per Kilobase of transcript per Million mapped reads). Transcripts with more than one exon and an expression level higher than 0.1 FPKM in at least one sample remained as high-confidence transcripts. Quantification and expression filtering were also performed on the TCGA (The Cancer Genome Atlas) data set.
iDeNtiFiCatioN oF HigHCoNFiDeNCe alteRNatiVe SpliCiNg eVeNtS
We used SUPPA (30) to calculate alternative splicing events (ASEs) by using the assembled transcript annotations and their quantification in our curated data sets and the TCGA LIHC cohort. Specifically, alternative splicing events were separately identified in curated and TCGA data sets. The PSI (percent spliced in) value was computed for every identified event in each sample. For each data set, the original ASEs were further processed to generate high-confidence events by retaining events with a PSI value greater than 0.1 in no less than 5% of samples. Then, events that occurred in both the curated and TCGA data sets were retained to form the final high-confidence set of ASEs. To detect differentially spliced events, we used the Wilcoxon singed-rank test to compare the PSI value distributions between paired normal and tumor samples. Multiple testing was corrected by using the Benjamini-Hochberg method to obtain the corrected P values. ASEs exhibiting a significant difference between normal and tumor samples with a median PSI >0.1 and a corrected P value <0.05 were considered differentially spliced.
eNRiCHMeNt aNalySiS oF DiFFeReNtially SpliCeD aSes
Protein-coding genes were extracted from corresponding differential ASEs (differentially spliced ASEs). Consequently, 5,346 protein-coding genes were associated with differential ASEs (1, (31) They collected 14 cellular processes/pathways that were closely related to Hallmarks of Cancer. These cellular processes/ pathways totally contain 2,172 genes, which were defined as cancer hallmark-related genes in our study. This set of hallmark genes was utilized to investigate their relationship with the genes included in each type of differential ASEs through enrichment analysis. In addition, ASEs regulated by differentially expressed RBPs were analyzed to explore the relevant pathways. All gene sets of the KEGG pathway were retrieved from Molecular Signature Database (MSigDB v6.0). (32) A hypergeometric test was performed to compute the enrichment significance. The probability P was calculated to evaluate the enrichment significance as follows:
where N is the total number of all genes, K represents the number of genes involved in the function category under investigation, M is the number of genes of interest for analysis, and x indicates the number of genes of interest involved in the investigated function category.
CoNStRUCtioN oF DySRegUlatioN NetWoRKS BetWeeN RBps aND aSes iN HCC
Expression level of RBP genes was expected to be correlated with the PSI level of target ASEs. Therefore, we calculated the Spearman correlation for each RBP-ASE pair. RBP-ASE pairs with Spearman correlation coefficients greater than 0.5 (or less than −0.5) and a corresponding P value (Benjamini-Hochberg corrected) less than 0.05 were considered significantly correlated. Then, two dysregulation networks were built, wherein RBP-ASE pairs containing both differentially expressed RBP genes and differentially spliced ASEs were first extracted. Specifically, the first network (high-confidence network) was further filtered by only retaining RBP-ASE pairs with RBPs that have predicted binding regions around corresponding splicing sites. The remaining RBP genes that showed differential expression, but no predicted binding regions, constituted the second network (predicted network). Additionally, a mutation network was constructed. In particular, the mutation network was based on RBPs that harbored deleterious single-nucleotide variations (SNVs; missense, nonsense, frame shift, in-frame, splicing, and translating start/end sites SNVs), whereas the expression-dysregulation network was based on RBPs that were differentially expressed in HCC tumor samples. In the mutation network, deleterious SNVs were detected in RBP genes or binding regions around splicing sites in paired ASEs.
StatiStiCal aNalySiS
All statistical computation and figure plotting in our study were performed in the R environment. (33) Additionally, statistical tests with a P value <0.05 were considered significant, unless indicated otherwise.
Results
tHe tRaNSCRiptioNal laNDSCape oF tHe HUMaN liVeR
To systematically characterize the human liver transcriptome, we collected 631 RNA-seq libraries, including 488 primary tumor, five relapse tumor, eight cell lines, 122 benign adjacent and 8 normal liver samples (Supporting Table S1 ; Supporting Methods). After the removal of low-quality reads, all raw sequencing data sets were qualified for downstream analysis (Supporting Fig. S1 ), then they were processed through a consistent bioinformatic pipeline (Supporting Fig. S2 ) to assemble and quantify
the liver transcriptome. Principal component analysis revealed consistent quality among the sequencing data from multiple centers, wherein tumor and nontumor samples were separated into different clusters (Supporting Fig. S3 ). These evaluations showed that the batch effect was acceptable for our collection of RNA-seq data.
Collectively, 298,868 transcripts were detected to express in the liver transcriptome. These transcripts were categorized into five types of genes (Fig. 1A) . Although a major fraction of the transcripts were annotated by GENCODE (v22), approximately one third were newly assembled (Fig. 1B) . Our coding potential prediction showed that the clear majority (81.3%) of unannotated transcripts were noncoding RNAs (Supporting Fig. S4 ; Supporting Table S2 ; Supporting Methods). These newly assembled noncoding RNAs might be new players underneath the development of HCC. As expected, multiple transcripts were detected for most of the genes. Specifically, over 70% of protein-coding and read-through genes had more than five transcripts for each gene, whereas approximately one third of long noncoding, pseudogenes, and unannotated genes had more than two transcripts (Fig.  1C) . Overall, transcripts from protein-coding and read-through genes were longer than those from other gene types (P < 2.2e-16, Wilcoxon rank-sum test; Supporting Fig. S5 ). Furthermore, we observed higher expression levels for protein-coding and read-through transcripts than for long noncoding and pseudogenes (Supporting Fig. S6A ). In addition, examination of active epigenetic marks showed that these epigenetic marks were significantly enriched around the transcription start sites of these transcripts, and the enrichment was also consistent with the transcription levels of different types of transcripts (Supporting Fig.  S6 ; Supporting Methods). This result suggests that these assembled transcripts are transcribed along with active promoters. Globally, assembled transcripts were more evolutionarily conserved than untranscribed genomic regions (Supporting Fig. S7 ). For all types of genes, intronic regions were less conserved than exonic regions (Supporting Fig. S7 ). To investigate genomic variants in different types of the assembled genes, we analyzed the SNV and copy number variation (CNV) data of a TCGA LIHC cohort (see Supporting Methods). In addition to a large number of variants in protein-coding genes, a number of variants were found located in noncoding genes (pseudogenes, long noncoding RNA [lncRNA], and unannotated genes; Fig. 1D,E) . Notably, around 60% of the genes located in CNV regions were noncoding genes ( Fig. 1D ; Supporting Table S3 ). Interestingly, approximately one fifth of the assembled genes that harbored SNVs have at least one SNV in splice sites or regions ( Fig.  1E ; Supporting Table S4 ). In summary, we assembled a relatively comprehensive transcriptome of human liver from different sample types. We found that most genes in the CNV regions in liver cancer were noncoding genes and also detected thousands of noncoding RNAs in the liver transcriptome.
aSes aRe pReValeNt iN HUMaN liVeR tRaNSCRiptoMe
Given that most genes have multiple transcripts in the assembled liver transcriptome, and AS is a major contributor to this transcriptional diversity, (9) we next identify ASEs from the assembled transcriptomic data (see Materials and Methods) to explore the multiplicity of the human liver transcriptome. In total, 287,500 high-confidence ASEs were detected ( Fig. 2A ). In addition, seven different types of ASEs were identified (Supporting Fig. S8 ), including SEs, MXs, A5s, A3s, RIs, AFs, and AL. Interestingly, AF and SE were the most frequently observed AS events, particularly in protein-coding and read-through genes (Fig. 2B) . We further analyzed and described features of ASEs and alternative exons. Overall, the length of most exons in these protein-coding genes were shorter than 200 base pairs (bp; Fig. 2C ), and most of the alternative internal exons (MX and SE exons) were much shorter than alternative exons that flank gene boundaries (P < 2.2e-16, Wilcoxon rank-sum test). In addition, less than half of alternative exons had intact codons (the length of intact codons is a multiple of three; Fig. 2D ). We further analyzed the detection frequency of ASEs with varying PSI levels in all samples. The results revealed that events with low PSI levels (PSI ≤ 0.2) constituted the majority of all types of ASEs (Fig. 2E ). These observations indicated that transcripts with splice-out alternative exons were the predominant transcribed form of most genes. Furthermore, differences between ASEs with distinct PSI levels were minor in both low-and high-frequency events (Fig. 2E) .
tHe laNDSCape oF DiFFeReNtially eXpReSSeD aSes iN HCC
To portray the full picture of aberrant alternative splicing that occurs in HCC, we identified differentially spliced events between tumor and paired adjacent normal samples (see Materials and Methods). In total, thousands of ASEs were detected as differentially spliced (Supporting Fig. S9 ; Supporting Table S5 ). As expected, protein-coding genes showed the greatest number of differentially spliced events. Most differential ASEs were detected in 20%-60% of tumor samples, approximately half of which were identified in more than 50% of patients (Fig. 3A) . Furthermore, the number of differential ASEs in distinct patients varied widely (from 5,000 to over 10,000). Although the number of detected differential ASEs varied among individuals, they shared similar patterns of ASE types (i.e., the proportional composition of differential ASE types is similar; Fig. 3B ). Distinct types of differential ASEs could be identified in the same genes (e.g., ADRA1A, LINC01348, and MEG3; Fig. 3C,D) , whereas some genes harbored a single type of differential ASE (e.g., GBA3, E2F2, and LINC00511). Some genes showed low-frequency detection of differential ASEs among tumor samples (e.g., NUMB, GAS5, and LIN28B; Fig.  3E ), whereas some genes were recurrently identified to be differentially spliced (e.g., ASPG, MELK, and LINC01348). In addition, single or several AS events were detected in different samples for some genes (e.g., TRPM8, GBA3, and MSTRG.55171; Fig. 3C ), but some genes presented multiple AS events in disparate tumor samples (e.g., LINC01348, ASPG, and MSTRG.32287). Among our list of differential ASEs, some were also detected in previous studies, such as MELK, (34) NUMB, (7) and USO1. (17) In addition to protein-coding genes, a variety of differential ASEs were also identified in lncRNA (such as LINC01348, PVT1, LINC00511, and KTN1-AS1), pseudogenes (such as GBA3 and NPY6R), and unannotated genes (such as MSTRG.32287 and MSTRG.55171), although they had relatively lower transcription complexity. Notably, this set of differential ASEs also contains genes reported to play important roles in tumor genesis and development. For example, one exon (chr17:43,091,435-43,094,860) of BRCA1, whose mutations have become a hallmark for hereditary breast cancer, (35) was used (spliced in) more often in tumor samples than in adjacent normal samples (Supporting Fig. S10 ). This implied the potential role of BRCA1 in HCC. These results suggest that abnormalities of ASEs varied among distinct samples and genes in liver cancer.
DiFFeReNtial aSes aRe CloSely RelateD to "CaNCeR HallMaRKS" aND CaN aCt aS RiSK pReDiCtoRS oF tHe oUtCoMe oF HCC patieNtS
To further explore the role that AS plays in liver cancer, enrichment analysis was performed on genes that harbor differential ASEs for cancer hallmarks (see Materials and Methods). Overall, the genes with differential ASEs were over-represented in such hallmarks as cell-cycle process, generation of precursor metabolites and energy, DNA repair, p53 signaling pathway, epithelial-mesenchymal transition (EMT), cell proliferation, and transforming growth factor (TGF)-beta signaling pathway ( Fig. 4A ; Supporting Table S6 ). Different types of ASEs were significantly over-represented in distinctive hallmarks. For example, only differential SE and AF ASEs were over-represented in cell proliferation. In addition, the TGF-beta signaling pathway was exceptionally enriched by differential ASEs of SE type. Intriguingly, in addition to the classical and common tumor signatures, such as cell-cycle process and DNA repair, the metabolism-related signature, generation of precursor metabolites and energy, was heavily influenced. We further investigated pathways in which differential ASE-related genes might participate. Although pathways such as pathways in cancer, focal adhesion, and cell cycle contain larger number of differential ASE-related genes, more metabolism-or biosynthesis-related pathways were significantly enriched ( Fig. 4B; Supporting Fig.  S11A ). Overall, 931 (17.5% of total genes that have differential ASEs) metabolism-related genes (genes involved in metabolism-related pathways and biological processes) showed differential ASEs, which are more predisposed than nonmetabolism genes (P < 2.2E-16, Chisq-test; Supporting Fig. S11B ). We also evaluated the clinical significance of differential ASEs in the TCGA LIHC cohort (see Supporting Methods). Consequently, 2,931 ASEs were found to significantly associate with patient survival (P < 0.05) in univariate Cox regression, wherein 1,216 ASEs were favorable (hazard ratio, <1) and 1,715 were unfavorable (Supporting Table S7 ). Additionally, our analysis revealed that alpha-fetoprotein status, HBV infection status, and tumor stage were significantly associated with patient survival (Supporting Fig. S13 ). In the following evaluation of the multivariate Cox hazard model, 243 ASEs were found to be significantly associated with survival (Supporting Table S8 ). Most of these ASEs were detected at low frequency (less than 30% of all samples; Fig. 4C ). Additionally, approximately half of the ASEs showed a wide range of PSI levels in tumor samples (Fig. 4D) . Our analysis also revealed that over two thirds of the ASEs were unfavorable factors (Fig. 4E) . Our analysis found that differential ASEs participated in many cancer-related biological process, especially metabolism-related pathways, and some of these differential ASEs were closely associated with survival of liver cancer patients. Some examples of Kaplan-Meier survival curves for differential ASEs are presented in Supporting Fig. S14 .
Because the differential ASEs heavily influenced the metabolism-related biological processes, we focused on these metabolism-related genes in particular. Among these metabolism-related genes, UGP2 (UDP-glucose pyrophosphorylase 2) is an important intermediary in mammalian carbohydrate interconversions. Among the abundantly expressed transcripts of UGP2, the alternative use of the first exons between transcripts ENST00000394417.5 and MSTRG41690.36 were identified (Fig. 5A ). UGP2 used "exon_F2" to a greater extent in normal samples, whereas "exon_F1" was expressed more highly in tumor samples ( Fig. 5B; Supporting Fig.  S12 ). Consequently, transcript ENST00000394417.5 showed significantly increased expression in tumors, whereas reduced expression was observed in tumors for transcript MSTRG.41690.36 (Fig. 5C) . The isoform switch of UGP2 might imply biological or clinical divergence for ENST00000394417.5 and MSTRG.41690.36. Further investigation revealed that patients with higher MSTRG.41690.36 expression survived for significantly longer times than low-expression patients (P = 0.00017, log-rank test), whereas expression variation of ENST00000394417.5 did not indicate any survival difference (Fig. 5D,E) . These results suggest that UGP2 might act as a suppressor through the AF event that produces higher expression of ENST00000394417.5 and lower MSTRG.41690.36 expression in liver cancer. 
tHe DySRegUlatioN NetWoRKS oF RBp WeRe eNRiCHeD iN MetaBoliSMRelateD patHWayS
RBPs have been shown to play roles in the splicing process. A substantial portion of deregulated ASEs might be subjected to modulation by differentially expressed RBPs. To further investigate the potential dysregulation of alternative splicing in liver cancer, we first examined the transcriptomic abnormality of RBP genes (see Supporting Methods). Consequently, 286 RBP genes were differentially expressed in tumor samples, including 231 up-regulated and 55 down-regulated RBP genes (Supporting Fig. S15 ). In addition, RBP-binding regions around splicing sites of differential ASEs were predicted using DeepBind (see Supporting Methods). The binding regions were detected in both exonic and intronic sequences, with a greater number found in exon regions and near the corresponding splicing sites (Supporting Fig. S16 ). We next paired differential ASEs with corresponding RBPs to construct RBP dysregulation networks (see Materials and Methods). Two regulatory networks were built, separated by whether the RBPs had predicted binding regions (high-confidence network and predicted network). In particular, the high-confidence network was composed of differential RBPs and their target ASEs with binding regions ( Fig. 6A ; Supporting Table S9 ), whereas the predicted network consisted of differential RBPs and their coexpressed differential ASEs ( Fig. 7A ; Supporting Table S10 ). In the high-confidence network, 13 RBPs regulated hundreds of differential ASEs that took part in many biological pathways (Fig. 6A ). SNRPA and RALY were observed to regulate a greater number of ASEs and pathways, which might play crucial roles in HCC (Fig. 6B) . Interestingly, RBM24 and SAMD4A regulated much fewer differential ASEs, but a relatively larger number of pathways. Among the pathways that contained the largest number of differential ASEs, most were metabolism-related pathways, such as metabolism of xenobiotics by cytochrome P450, retinol metabolism, and drug metabolism cytochrome P450. Although pathways such as pathways in cancer and cell cycle were also involved with a large number of differential ASEs, they had lower enrichment significance than metabolism-related pathways (Fig. 6C) . In addition, the predicted network comprised 216 up-expression and 28 down-expression RBP genes ( Fig. 7A ; Supporting Table S11 ). Among these RBPs, EIF4A1, SRSF5, SYNE1, CLK2, and EZH2 regulated the greatest number of differential ASEs (Fig. 7B) , whereas CSTB, GAPDH, RPSA, CLK2, SRSF5, and EIF4A1 regulated the greatest number of involved pathways (Fig. 7C) . Furthermore, the top enriched pathways were metabolism-related pathways such as starch and sucrose metabolism, porphyrin and chlorophyll metabolism, and drug metabolism other enzymes (Fig. 7D ). Our observations show that RBPs regulated major metabolism-related pathways through ASEs in liver cancer, and RBPs in the center of the regulatory network might play more important roles in the development of liver cancer, such as SNRPA, RALY, EIF4A1, and SRSF5.
In addition to transcriptomic variations, binding of RBPs to RNA sequences could be intervened by variations in the sequence of RBP genes and target binding regions. We found that hundreds of RBP genes harbored deleterious SNVs, approximately three quarters of which were not differentially expressed in tumor samples (Supporting Fig. S18A ; Supporting Table S12 ). The SF3B1 gene encodes subunit 1 of the splicing factor 3B protein complex, the valid expression variation of which was not identified in the queried data sets (Supporting Fig. S18B ). In the coding region of the SF3B1 gene, 10 missense mutations were detected, five of which were in the heat domains that form rod-like helical structures (Supporting Fig.  S18C ). These mutations might affect binding between SF3B1 protein and its target RNAs. Furthermore, in the binding regions of RBP around splicing sites, deleterious mutations were observed in hundreds of differential ASEs for each ASE type (Supporting Fig.  S18D ). Most of the differential ASEs were coupled with multiple RBPs through mutations in binding regions, particularly for SE and A3 ASEs. The clear majority of mutations occurred in a small proportion of samples, although a large number of RBP genes and binding regions were found to harbor deleterious mutations (Supporting Fig. S18A ). However, numerous differential ASEs and corresponding RBPs could target the same genes. That is, the effect of mutations in RBP genes and binding regions could be exerted on the same genes. The combination of mutations in both corresponding RBPs and binding regions resulted in high-frequency detection in samples for 1,217 genes (Supporting Figs. S18E and S19; Supporting Table S12 ).
Discussion
Based on the tremendous amount of high-throughput RNA-seq data derived from samples related to HCC, we present an overall portrait of transcription in HCC. In addition to samples originating from primary tumor and adjacent normal tissue used by most studies, we integrated relapse HCC tumor, normal liver tissue, and HCC cell lines. Further transcriptome assembly guided by GENCODE annotation (release 22) generated a highly abundant landscape of transcripts. Thus, we obtained a more comprehensive repertoire of AS in HCC than that reported in previous studies. (16, 17) We compared transcripts detected from different sample types and found that although most transcripts can be identified in all sample types, some portion of them only appeared in certain sample types (Supporting Fig. S20A ). We further analyzed the sample-type-specific transcripts. Our results showed that the majority of sample-type-specific transcripts were noncoding, most of which were unannotated transcripts. In addition, primary tumor samples have a relatively higher portion of specific protein coding transcripts (Supporting Fig. S20B ). Given that protein coding transcripts showed much higher abundance (Supporting Fig. S6A ), these specific transcripts could be potential markers for diagnosis of primary liver cancer. Thus, we combined all the transcripts to get a more comprehensive transcriptome of liver cancer. Furthermore, around 66% of ASEs that were identified in tumor samples can be detected in cell lines (Supporting Fig. S21A ). Over 95% of ASEs that were identified in each cell line can be detected in tumor samples. These cell lines represent pure liver cancer cells that originate from different sites or stages of liver cancer. The comparison among cell lines showed that, on average, over 30% of ASEs detected in one cell line were different from another cell line (Supporting Fig.  S21B ). Therefore, distinct biological features of these cell lines reflect heterogeneity of liver cancer. Among the seven types of detected ASEs, AF (alternative first exon) event was the most frequently observed ASE type in HCC, closely followed by SE (skipping exon) events. SE events are supposed to be the most common splicing patterns in the mammalian transcriptome, in part because of the investigated areas that are restricted within intragenic regions and the limits of sequencing technology. (11, 36) With the improvement of high-throughput RNA-seq technology and abundant transcript annotation, an increasing number of transcript variants generated from the alternative use of transcription start sites are found to play roles in tumors. (37) (38) (39) DNA repeats are reported to be among the most variable loci in the human genome, whose instability is associated with gene expression changes and involved in human carcinomas. (40, 41) We searched the upstream regions of differential AF events for DNA repeat sequences. Consequently, almost all differential AF events were found to contain repeat sequences within upstream regions (Supporting Fig. S22 ; Supporting Table S13 ). Most differential AF events harbored multiple repeats within the upstream regions, among which SINE, LINE, LTR and Simple_repeat were the most frequently observed repeats (Supporting Fig. S22B,C) . Furthermore, changes in transcription markers (such as H3K4Me3 and H3K27ac) were observed within promoter regions of alternative transcripts that were generated from differential AF events (Supporting Fig. S22D ; Supporting Table S14 ). For example, the signal of H3K4me3 within the promoter region of ENST00000394417.5, which is a transcript generated from the alternative use of the UGP2 first exon, was observed to notably increase in liver tumors (Supporting Fig. S23 ). In addition, appreciable Pol II signal intensity was observed within promoter regions of ENST00000394417.5 in HCC cells. The upstream repeats and varied transcriptional marks might be potential regulatory elements for differential AF events, although their activity and instability in HCC need to be further explored.
RBP performs crucial modulation during RNA splicing. We identified 286 differentially expressed RBP genes in HCC and further constructed RBP dysregulation networks. Because of the limited amount of experimental RBP binding evidence available, our high-confidence network contains only 13 RBP genes. To supplement the RBP dysregulation network, a predicted network based on the coexpression relationship between RBP genes and corresponding ASEs was built. In addition, another network based on deleterious mutations in RBP genes and binding regions elucidates the dysregulation from a different perspective. These networks are powerful resources for further investigating AS dysregulation in HCC. We believe that a large part of the relationship built in this study will be verified with the emergence of improved biotechnology for RBP binding detection and growing publicly available resources.
Compared to a previous study that focused on HBV-and HCV-associated HCC, (42) we identified many more ASEs (280,000 vs. 45,000) and include not only protein-coding, but noncoding and unannotated genes. By comparing paired tumor and adjacent normal samples, we demonstrated that a significant number of differential ASEs affected genes involved in metabolic processes and found that some genes showed transcripts switch in liver cancer, such as UGP2. Furthermore, we investigated and constructed RBP-ASE regulation networks in liver cancer. We also identified some ASEs that were significantly associated with patient survival, which could serve as potential biomarkers in the clinic.
In summary, we presented a comprehensive portrait of transcription complexity and systematically characterized the dysregulation of AS and its biological/ clinical implications in HCC. The dysregulation of AS conducted by RBP was also described. Our results demonstrated that differentially expressed ASEs frequently occurred in HCC, highly related to cancer hallmarks, and could act as risk predictors of HCC patient survival. The resource we provided will be helpful for the understanding and exploration of transcription diversity in HCC, which is anticipated to inspire fundamental studies and precision medicine in HCC.
